Innoviva’s (INVA) Neutral Rating Reaffirmed at Stifel Nicolaus

Stifel Nicolaus reiterated their neutral rating on shares of Innoviva, Inc. (NASDAQ:INVA) in a research note published on Friday morning.

INVA has been the topic of several other reports. ValuEngine lowered Innoviva from a buy rating to a hold rating in a research report on Friday, June 2nd. Zacks Investment Research lowered Innoviva from a hold rating to a sell rating in a research report on Monday, July 3rd. Cowen and Company set a $16.00 target price on Innoviva and gave the stock a buy rating in a research report on Friday, July 28th. Finally, Robert W. Baird reaffirmed a neutral rating and issued a $13.00 target price (up from $11.00) on shares of Innoviva in a research report on Thursday, July 27th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Innoviva currently has an average rating of Hold and an average price target of $15.00.

Innoviva (NASDAQ:INVA) traded down 1.28% during trading on Friday, hitting $13.87. The stock had a trading volume of 1,951,604 shares. Innoviva has a 12-month low of $8.67 and a 12-month high of $14.55. The company has a 50 day moving average of $13.18 and a 200-day moving average of $12.78. The company has a market cap of $1.52 billion, a P/E ratio of 17.45 and a beta of 2.58.

Innoviva (NASDAQ:INVA) last posted its quarterly earnings results on Wednesday, July 26th. The biotechnology company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.02. Innoviva had a negative return on equity of 27.37% and a net margin of 52.56%. The firm had revenue of $58.60 million for the quarter, compared to analyst estimates of $50.53 million. During the same period in the previous year, the firm earned $0.13 earnings per share. Innoviva’s quarterly revenue was up 80.3% on a year-over-year basis. On average, equities analysts predict that Innoviva will post $1.16 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/09/16/innovivas-inva-neutral-rating-reaffirmed-at-stifel-nicolaus.html.

A number of hedge funds have recently modified their holdings of INVA. BlackRock Inc. increased its position in Innoviva by 68,215.3% in the 1st quarter. BlackRock Inc. now owns 12,000,259 shares of the biotechnology company’s stock worth $165,964,000 after purchasing an additional 11,982,693 shares during the last quarter. FMR LLC increased its position in Innoviva by 5.3% in the 2nd quarter. FMR LLC now owns 16,017,256 shares of the biotechnology company’s stock worth $205,021,000 after purchasing an additional 802,605 shares during the last quarter. Marshall Wace North America L.P. increased its position in Innoviva by 3,296.8% in the 2nd quarter. Marshall Wace North America L.P. now owns 822,356 shares of the biotechnology company’s stock worth $10,691,000 after purchasing an additional 798,146 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in Innoviva in the 1st quarter worth about $9,852,000. Finally, Dimensional Fund Advisors LP increased its position in Innoviva by 651.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 801,994 shares of the biotechnology company’s stock worth $10,266,000 after purchasing an additional 695,272 shares during the last quarter. 69.07% of the stock is currently owned by institutional investors.

About Innoviva

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Receive News & Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply